News Archive

A $90 million award expected from the National Institute of Aging and the National Heart, Lung, & Blood Institute will fund the largest pragmatic trial with placebo-controlled drug assignm

Investigators will develop a core set of endpoints and measures to be used in clinical trials and spur development of new pain medications for young children.

Of patients studied, only one-third of those who had had a stroke were receiving guideline-recommended statin therapy, while nearly a quarter of these patients were not receiving any statins.

Mixed results from the CABANA trial have led to debate about whether catheter ablation is an effective treatment option that provides benefit to patients with atrial fibrillation.

Research from DCRI investigators will help determine whether medications prescribed off-label to individuals with Down syndrome are safe and effective.

A new faculty member has joined the DCRI’s musculoskeletal group.

Research guidance recently issued by the FDA provides clarity regarding clinical trial study design, drug dosing, and analysis in studies of newborns.

The meeting summary highlights gaps in evidence about the dangers of vaping and e-cigarette use to youth, as well as key takeaways and strategies to combat youth tobacco use.

Recently published results explore reasons behind the well-documented phenomenon of gendered differences in statin use.

Evidence supports that implantable cardioverter defibrillators still provide life-saving benefits, but more research is needed to improve the selection of patients for this treatment.